AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03073954 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Working memory training
Description: The working memory intervention training programme consists of a domain-general cognitive working memory training programme. One training session will take 20 to 30 minutes, and participants will have to complete approximately 40 cognitive training sessions.~The sham treatment is the same as the intervention training however it does not increase in difficulty. Participants are presented with the same task at the same level of difficulty over and over again. Thus a training effect is not expected.
Study NCT03073954 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Standardised healthy lifestyle coaching
Description: Participants will receive standardised healthy living coaching focusing on healthy diet and daily physical activity.
Study NCT03073954 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standardised healthy lifestyle coaching
Description: Participants will receive standardised healthy living coaching focusing on healthy diet and daily physical activity.
Study NCT01564628 — intervention group
Intervention type: DEVICE
Intervention: CADScor1
Description: Acoustic recording
Study NCT01735851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural analgesia
Study NCT01735851 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Paravertebral block
Study NCT01442831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human ADME
Description: Oral single dose
Study NCT02299492 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Person Centered Care Planning
Description: PCCP is a manualized provider-based intervention that maximizes consumer choice for adults receiving mental health services. PCCP focuses on engagement and individualized care, thereby enhancing the impact of existing evidence based practices.
Study NCT03557580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IS-5-MN R
Description: single orally dose under fed conditions on day 1 of treatment period 1 for group 1, on day 1 of treatment period 2 for group 2, on day 1 of treatment period 3 for group 3.
Study NCT03557580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IS-5-MN T1
Description: single orally dose under fed conditions on day 1 of treatment period 2 for group 1, on day 1 of treatment period 3 for group 2, on day 1 of treatment period 1 for group 3.
Study NCT03557580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IS-5-MN T2
Description: single orally dose under fed conditions on day 1 of treatment period 3 for group 1, on day 1 of treatment period 1 for group 2, on day 1 of treatment period 2 for group 3.
Study NCT01201265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg iv every 3 weeks
Study NCT01201265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: to an AUC = 2, on days 1 and 8 of each 3-week cycle
Study NCT01201265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 iv on days 1 and 8 of each 3-week cycle
Study NCT04377750 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tocilizumab
Description: The placebo treatment arm will include 100 ml of normal saline administered along 60 min
Study NCT04377750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: The placebo treatment arm will include 100 ml of normal saline administered along 60 min
Study NCT02844647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Pyruvate (13C)
Description: MRI contrast agent
Study NCT03795597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib is an anti-cancer drug acting as a selective proteasome inhibitor that is used to treat Multiple Myeloma.
Study NCT03795597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan IV
Description: Busulfan is an anti-cancer drug acting as a bifunctional alkylating agent that is used to treat Multiple Myeloma.
Study NCT03795597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan IV
Description: Melphalan is an anti-cancer drug acting as alkylating agent that is used to treat Multiple Myeloma.
Study NCT01572753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 120 mins, no food or liquid is allowed.
Study NCT01572753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 60 mins, no food or liquid is allowed.
Study NCT01572753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 30 mins, no food or liquid is allowed.
Study NCT01572753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 15 mins, no food or liquid is allowed.
Study NCT01572753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 120 mins, no food or liquid is allowed.
Study NCT01572753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 60 mins, no food or liquid is allowed.
Study NCT01572753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 30 mins, no food or liquid is allowed.
Study NCT01572753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 15 mins, no food or liquid is allowed.
Study NCT03712358 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PVSRIPO
Description: Intralesional injection of PVSRIPO.
Study NCT02374450 — intervention group
Intervention type: PROCEDURE
Intervention: Blood collection
Description: For all hospitalised children suspected of having an AESI or meningitis, a sample of 5 ml of whole blood was collected and the serum was stored.
Study NCT04910789 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transhiatal/transabdominal approach
Description: Radical surgery should be finished via transhiatal/transabdominal approach
Study NCT04910789 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thoracoabdominal approach
Description: Radical surgery should be finished via thoracoabdominal approach
Study NCT02325479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enaoxaprin sodium
Description: intrauterine administration after oocyte pickup as the main experimental intervention
Study NCT02325479 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tissue culture media
Description: intrauterine administration after oocyte pickup as placebo
Study NCT03011320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC1456
Description: intravenous (IV) bolus dose
Study NCT03011320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-Etarfolatide
Description: Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) \[20 to 25 millicuries (mCi)\] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.
Study NCT00089297 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Induction: An initial dose of cetuximab (C225) 400 mg/m2 (over 2 hours) was given week 1 only. Then, C225 was administered at dose of 250 mg/m2 (over 1 hour) weekly for 5 weeks.~Concurrent Chemoradiation (Weeks 9-13): C225 was administered at 250 mg/m2/wk (over 1 hour).~Restaging Biopsy of Primary Site (Week 14): Patients with positive biopsy of the primary site at week 7 or patients without a clinical complete response at the primary site after induction therapy were scheduled for re-biopsy of the primary site at week 14 after concurrent therapy (50 Gy). If the biopsy were negative after concurrent therapy, the patients were scheduled to continue concurrent therapy to complete radiation (68-72 Gy).~Additional Concurrent Chemoradiation (weeks 15, 16 and 17): Concurrent therapy was consisted of C225 at 250mg/m2/week IV over 1 hour followed by paclitaxel 30mg/m2/week IV over 1 hour followed by carboplatin AUC = 1/week over 15 minutes and RT for three weeks.
Study NCT00089297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Induction Therapy (Week 1-6): The induction chemotherapy starting at week 1 included paclitaxel 90 mg/m2 IV over 1 hour weekly and carboplatin AUC = 2 IV over 30 minutes weekly. The paclitaxel and carboplatin doses were given on the same day, 1 hour after C225 dose was administered. For paclitaxel and carboplatin therapy, rounding of doses (to next decimal if above 0.5 and to lower decimal if below 0.5) was permitted.~Concurrent Chemoradiation (Weeks 9-13): Concurrent chemotherapy was consisted of paclitaxel following cetuximab at 30 mg/m2/wk (over 1 hour) and carboplatin following paclitaxel at AUC = 1/week (over 15 minutes).~Additional Concurrent Chemoradiation (weeks 15, 16 and 17): Concurrent therapy was consisted of C225 at 250mg/m2/week IV over 1 hour followed by paclitaxel 30mg/m2/week IV over 1 hour followed by carboplatin AUC = 1/week over 15 minutes and RT for three weeks.
Study NCT00089297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Induction Therapy (Week 1-6): The induction chemotherapy starting at week 1 included paclitaxel 90 mg/m2 IV over 1 hour weekly and carboplatin AUC = 2 IV over 30 minutes weekly. The paclitaxel and carboplatin doses were given on the same day, 1 hour after C225 dose was administered. For paclitaxel and carboplatin therapy, rounding of doses (to next decimal if above 0.5 and to lower decimal if below 0.5) was permitted.~Concurrent Chemoradiation (Weeks 9-13): Concurrent chemotherapy was consisted of paclitaxel following cetuximab at 30 mg/m2/wk (over 1 hour) and carboplatin following paclitaxel at AUC = 1/week (over 15 minutes).~Additional Concurrent Chemoradiation (weeks 15, 16 and 17): Concurrent therapy was consisted of C225 at 250mg/m2/week IV over 1 hour followed by paclitaxel 30mg/m2/week IV over 1 hour followed by carboplatin AUC = 1/week over 15 minutes and RT for three weeks.
Study NCT00089297 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Concurrent Chemoradiation (Weeks 9-13): Radiation was given at 200cGy/d/5 weeks for a total dose of 50Gy (5000 cGy). Patients with a negative initial biopsy at week 7 were scheduled to continue concurrent therapy to complete radiation (68-72Gy).~If the biopsy was negative after concurrent therapy, the patients were scheduled to continue concurrent therapy to complete radiation (68-72 Gy).~Additional Concurrent Chemoradiation (weeks 15, 16 and 17): Concurrent therapy was consisted of C225 at 250mg/m2/week IV over 1 hour followed by paclitaxel 30mg/m2/week IV over 1 hour followed by carboplatin AUC = 1/week over 15 minutes and RT for three weeks.
Study NCT00506987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 486757
Description: SCH 486757 2 x 50-mg capsule twice daily orally for 2 weeks followed by a 2-week washout period and 2 weeks of crossover treatment
Study NCT02030808 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Muscle Relaxants (MR) group
Description: patients received 0.2 mL/kg cisatracurium® (Nimbex) 0.2%, and a left-sided endobronchial double-lumen tube was placed when the TOF revealed one or two twitches
Study NCT02030808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non- Muscle Relaxants (NMR) group
Description: No cisatracurium® (Nimbex) will be administered
Study NCT03828825 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patent Foramen Ovale closure
Description: The Patent Foramen Ovale closure is realized under trans-thoracic echocardiography control. If necessary, the operator will use trans-esophageal echocardiography to implant the prosthesis. One day after the procedure, a clinical assessment and an electrocardiogram are performed. At 3 months the consultation corresponds to a trans-thoracic echocardiography validation of the closure accompanied by a bubble test (Valsalva maneuver) and a clinical assessment. At 12 months, the visit corresponds to a consultation with a clinical assessment and an electrocardiogram. At 36-months and 60-months, the visits will be done following the on-site visits provided for in the usual care or during a telephone call from the attending cardiologist to retrieve the results of the clinical examination, electrocardiogram and MACCE (major cardiac and cerebral vascular events). A consultation dedicated to the study may be proposed to patients according to what is provided in the usual care.
Study NCT01786005 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Study NCT01786005 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial magnetic stimulation
Study NCT03706417 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Telemedicine consult
Description: Utilizing telemedicine in community hospital for earlier identification of symptoms of neonatal encephalopathy.
Study NCT00852683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: 75 mg twice a day
Study NCT00852683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 75 mg twice a day
Study NCT01999881 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention
Description: Receive aerobic and exercise intervention
Study NCT01999881 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard follow-up care
Description: Receive usual care
Study NCT01999881 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01999881 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01999881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01999881 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03077971 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT Self-Help
Description: Self-Help Intervention Workbook using an Acceptance and Commitment Therapy approach
Study NCT03077971 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT Self-Help with Telephone Support
Description: Self-Help Intervention Workbook using an Acceptance and Commitment Therapy approach alongside weekly telephone support calls
Study NCT02403128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept
Description: Intravitreal injection of 2.0 mg aflibercept at baseline, and repeated no sooner than two months from the previous injection for persistent macular edema as defined in the protocol.
Study NCT02799446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reslizumab
Description: Reslizumab 3mg/kg intravenous (IV)
Study NCT02799446 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo intravenous (IV)
Study NCT03128294 — intervention group
Intervention type: OTHER
Intervention: Retrospective, cross-sectional descriptive analysis
Description: This study is a retrospective, cross-sectional descriptive analysis, and concerns the extraction of data from anonymised patient files. A database will be constructed and descriptive statistics will be used to summarise the data.
Study NCT02195518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: Tenofovir disoproxil fumarate tablets supplied will be white, almond-shaped, film-coated tablets containing 300 mg of TDF. Each tablet contains the following inactive ingredients: microcrystalline cellulose, lactose monohydrate, pregelatinised starch, croscarmellose sodium, and magnesium stearate.
Study NCT01517399 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: tivantinib
Description: three oral 120 mg tablets administered twice a day
Study NCT01517399 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: omeprazole
Description: One 40 mg oral capsule once alone and once again with tivantinib
Study NCT01517399 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: s-warfarin
Description: One 10 mg oral tablet once alone and once again with tivantinib
Study NCT01517399 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: caffeine
Description: One 200 mg oral tablet once alone and once again with tivantinib
Study NCT01517399 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: vitamin K
Description: One oral 5 mg tablet on multiple days when and around warfarin administration
Study NCT01517399 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: digoxin
Description: One oral 0.25 mg tablet once alone and once again with tivantinib
Study NCT00506987 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Dose 1
Description: Matching placebo capsules twice daily orally for 2 weeks followed by a 2 week washout period and 2 weeks of crossover treatment
Study NCT04015999 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Microbiota Directed Complementary Food (MDCF)
Description: MDCF2 with four complementary food ingredients (rationale: lead with evidence from Pre-POC clinical trials to optimize lead microbiota-directed complementary food prototypes for their ability to repair microbiota immaturity and positive effects on growth)
Study NCT04015999 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ready to Use Supplementary Food (RUSF)
Description: Rice-lentil based RUSF (rationale: reference standard of care for MAM; based on knowledge of its effects on the gut microbiota or microbiota immaturity)
Study NCT01280110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxypropylmethylcellulose
Description: 22 patients will receive this lubricating drop 4 times a day for 1 month
Study NCT01280110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboxymethylcellulose
Description: 22 patients will receive this lubricating drop 4 times a day for 1 month.
Study NCT01517399 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: midazolam
Description: Intravenous 1.5 mg dose once alone and once again with tivantinib
Study NCT03516929 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: carotid duplex, both LL arterial duplex
Description: assessment of carotid stenosis and lower limb peripheral ischemia.
Study NCT03516929 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: carotid duplex, both LL arterial duplex
Description: assessment of carotid stenosis and lower limb peripheral ischemia.
Study NCT03716700 — intervention group
Intervention type: BIOLOGICAL
Intervention: CUVITRU
Description: CUVITRU
Study NCT00976612 — intervention group
Intervention type: DRUG
Intervention: Nilotinib
Description: Nilotinib 400mg bid daily
Study NCT02757235 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Irrigation fluid of body temperature
Description: Irrigation fluid of body temperature will be used during burr hole evacuation of chronic subdural hematoma
Study NCT02757235 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Irrigation fluid of room temperature
Description: Irrigation fluid of room temperature will be used during burr hole evacuation of chronic subdural hematoma.
Study NCT00906204 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Single-dose rabbit Anti-thymocyte Globulin induction
Description: 6 mg of rATG administered in a single dose on the day of kidney transplantation
Study NCT00906204 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Divided-dose rabbit Anti-thymocyte Globulin induction
Description: 6 mg/kg total rabbit Anti-thymocyte Globulin dose administered as 1.5 mg/kg doses on 4 sequential days, beginning on the day of kidney transplantation.
Study NCT03333343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGF816
Description: Study Drug
Study NCT03333343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trametinib
Description: Study Drug
Study NCT03333343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribociclib
Description: Study Drug